Decoding Novo Nordisk's Options Activity: What's the Big Picture?
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
Novo Nordisk's new CagriSema obesity drug trial to begin on Feb. 10, clinicaltrials.gov entry shows
Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, according to a entry.
Novo Nordisk says it has not yet posted details about new CagriSema trial
Novo Nordisk said on Thursday it has not yet posted details about a new trial of its experimental next-generation obesity drug CagriSema, which it announced it would start after late-stage trial data ...
Hosted on MSN21d
UBS Upgrades Novo Nordisk A (NVO)
The firm decreased its portfolio allocation in NVO by 19.07% over the last quarter. Novo Nordisk Background Information (This description is provided by the company.) Novo Nordisk A/S is a Danish ...
Health Care Up on Novo Nordisk Optimism -- Health Care Roundup
Health-care companies rose as traders rotated back into the sector amid optimism about blockbuster drugs. Novo Nordisk shares rose by more than 8% for one of their biggest gains in recent years after ...
FiercePharma27d
Novo asks FDA to restrict Victoza compounding amid GLP-1 outsourcing row
Novo Nordisk’s efforts to ward off competition against its aging diabetes blockbuster Victoza have been quietly simmering in the background. In a citizen petition posted by the FDA this week ...
pharmaphorum5d
Novo Nordisk once-weekly insulin clears first phase 3 test
Basal insulin therapy, currently administered either once or twice daily, is a well-established therapy for diabetes, providing a background ... as daily dosing with Novo Nordisk's Tresiba ...
FiercePharma2d
Novo Nordisk expands Ozempic's turf with new FDA nod to curb kidney disease risks
When Novo Nordisk unveiled kidney outcomes data for its star GLP-1 medicine Ozempic last May, the company’s executive medical ...